Understanding B7x in Cancer Treatment
The B7x pathways in the tumor microenvironment
This research explores new ways to boost the body's immune response against cancer, especially for patients who haven't responded to existing treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11002277 on NIH RePORTER |
What this research studies
Many people with cancer do not respond to current immune-boosting treatments, which presents a significant challenge. This project focuses on two specific immune system regulators, B7x and HHLA2, that we believe play a key role in helping tumors hide from the body's defenses. Our goal is to understand how these regulators work within tumors to suppress the immune system. By uncovering these mechanisms, we aim to create new types of immunotherapy that can overcome resistance to current treatments and help more patients fight their cancer.
Who could benefit from this research
Good fit: This research is foundational for developing new treatments for cancer patients, especially those whose tumors are resistant to existing immune checkpoint therapies.
Not a fit: Patients who respond well to current immune checkpoint therapies may not directly benefit from this specific research, as it focuses on alternative pathways.
Why it matters
Potential benefit: If successful, this work could lead to new immunotherapies for cancer patients, particularly those who do not benefit from current treatments.
How similar studies have performed: While immune checkpoint blockade has shown success with other targets like PD-1/PD-L1 and CTLA-4, this research explores less-studied B7 family members, offering a novel approach.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Zang, Xingxing — Albert Einstein College of Medicine
- Study coordinator: Zang, Xingxing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.